Enjoy complimentary customisation on priority with our Enterprise License!
Below are some of the key findings from this myelofibrosis therapeutics market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The need for disease-modifying drugs for myelofibrosis is driving its therapeutics market. The only FDA approved drug therapy for myelofibrosis is JAKAVI/JAKAFI, but it has dose-related side effects that tend to halt the disease progression to acute leukemia. Other drugs and steroids prescribed by a physician are the off-label ones, which merely focus on prolonging the survival along with the disease. Hematopoietic stem cell transplantation (HSCT) therapy is also having disadvantages regarding the unavailability of matching donors and other therapies only reduce the anemic side-effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can help in eradicating the disease completely, which makes the need for disease-modifying drugs for myelofibrosis important, driving the myelofibrosis therapeutics market growth at a CAGR of more than 7% during the forecast period.
The global myelofibrosis therapeutics market is extremely concentrated. The market is in the initial stage of the growth phase, and the competition is expected to become less intense by the end of the forecast period. To help clients improve their revenue shares in the market, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this myelofibrosis therapeutics market analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.
The report offers a detailed analysis of several leading companies, including:
Drug therapy held the largest share of the global myelofibrosis therapeutics market in 2017. The market share of this segment will increase, and it will continue to dominate the market throughout the next five years.
The Americas accounted for the largest myelofibrosis therapeutics market share in 2017. This region will witness an increase in its market share and remain the market leader for the next five years.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
PART 15: VENDOR ANALYSIS
PART 16: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.